Definium Therapeutics(DFTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DFTX Definium Therapeutics

Market Closed 03-06 16:00:00 EST

17.66

+0.11

+0.63%

盘后17.55

-0.11-0.62%

19:58 EST

High17.90	Low16.87	Vol957.32K
Open17.19	D1 Closing17.55	Amplitude5.87%
Mkt Cap1.76B	Tradable Cap1.66B	Total Shares99.70M
T/O16.80M	T/O Rate1.02%	Tradable Shares93.74M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":17.66,"timestamp":1772830800000,"preClose":17.55,"halted":0,"volume":957319,"hourTrading":{"tag":"盘后","latestPrice":17.55,"preClose":17.66,"latestTime":"19:58 EST","volume":34282,"amount":605340.2816,"timestamp":1772845084032,"change":-0.11,"changeRate":-0.006229,"amplitude":0.006229},"delay":0,"changeRate":0.006267806267806235,"floatShares":93736700,"shares":99698129,"eps":-2.059999,"marketStatus":"Market Closed","change":0.11,"latestTime":"03-06 16:00:00 EST","open":17.19,"high":17.9,"low":16.8705,"amount":16800743.583734002,"amplitude":0.058661,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.059999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773043200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":17.55,"preHourTrading":{"tag":"盘前","latestPrice":17.4,"preClose":17.55,"latestTime":"09:27 EST","volume":1519,"amount":26135.6102,"timestamp":1772807270167,"change":-0.15,"changeRate":-0.008547,"amplitude":0.018803},"postHourTrading":{"tag":"盘后","latestPrice":17.55,"preClose":17.66,"latestTime":"19:58 EST","volume":34282,"amount":605340.2816,"timestamp":1772845084032,"change":-0.11,"changeRate":-0.006229,"amplitude":0.006229},"volumeRatio":0.4071664423912213,"impliedVol":0.9462,"impliedVolPercentile":0.9118},"requestUrl":"/m/hq/s/DFTX","defaultTab":"news","newsList":[{"id":"1132686136","title":"Stock Track | Definium Therapeutics Soars 5.24% Intraday on Analyst Buy Rating and $26 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1132686136","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132686136?lang=en_us&edition=fundamental","pubTime":"2026-03-04 04:24","pubTimestamp":1772569464,"startTime":"0","endTime":"0","summary":"Definium Therapeutics' stock surged 5.24% during intraday trading on Tuesday, following a positive analyst update.The movement comes after Evercore ISI analyst Gavin Clark-Gartner maintained a Buy...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["DFTX"],"gpt_icon":0},{"id":"2616348316","title":"Evercore ISI Sticks to Their Buy Rating for Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616348316","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616348316?lang=en_us&edition=fundamental","pubTime":"2026-03-03 17:16","pubTimestamp":1772529373,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Definium Therapeutics yesterday and set a price target of $26.00. The company’s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-sticks-to-their-buy-rating-for-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-sticks-to-their-buy-rating-for-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"gpt_icon":0},{"id":"2616253358","title":"Definium Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2616253358","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616253358?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:13","pubTimestamp":1772460780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DFTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 09:13 ET (14:13 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"gpt_icon":0},{"id":"2616331829","title":"Definium Therapeutics (DFTX) Receives a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2616331829","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616331829?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:57","pubTimestamp":1772452651,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Definium Therapeutics today and set a price target of $70.00. According to TipR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/definium-therapeutics-dftx-receives-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/definium-therapeutics-dftx-receives-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","DFTX"],"gpt_icon":0},{"id":"2616031849","title":"Definium Therapeutics Advances DT120 ODT As Trials And Valuation Gain Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2616031849","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616031849?lang=en_us&edition=fundamental","pubTime":"2026-03-01 05:25","pubTimestamp":1772313957,"startTime":"0","endTime":"0","summary":"Definium Therapeutics' lead asset, DT120 ODT, has received FDA Breakthrough Therapy Designation for generalized anxiety disorder.\nThe company is approaching pivotal phase III readouts across multiple late stage trials and has launched a new phase II study in autism spectrum disorder.\nDefinium is also increasing its commercial readiness by expanding leadership and building operational infrastructure as it moves toward a potential launch phase.\n\nFor investors watching NasdaqGS:DFTX, this...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dftx/definium-therapeutics/news/definium-therapeutics-advances-dt120-odt-as-trials-and-valua","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dftx/definium-therapeutics/news/definium-therapeutics-advances-dt120-odt-as-trials-and-valua","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","DFTX","ODT"],"gpt_icon":0},{"id":"2614758853","title":"Canaccord Genuity Remains a Buy on Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614758853","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614758853?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:39","pubTimestamp":1772195968,"startTime":"0","endTime":"0","summary":"In a report released today, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Definium Therapeutics, with a price target of $25.00....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2614875518","title":"Definium Therapeutics: Late-Stage Pipeline Progress and Upcoming Phase 3 Readouts Support Buy Rating and Favorable Risk-Reward","url":"https://stock-news.laohu8.com/highlight/detail?id=2614875518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614875518?lang=en_us&edition=fundamental","pubTime":"2026-02-27 15:45","pubTimestamp":1772178357,"startTime":"0","endTime":"0","summary":"Definium Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia from Needham reiterated a Buy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/definium-therapeutics-late-stage-pipeline-progress-and-upcoming-phase-3-readouts-support-buy-rating-and-favorable-risk-reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/definium-therapeutics-late-stage-pipeline-progress-and-upcoming-phase-3-readouts-support-buy-rating-and-favorable-risk-reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","PRGS","SSI"],"gpt_icon":0},{"id":"2614074658","title":"Definium Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2614074658","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614074658?lang=en_us&edition=fundamental","pubTime":"2026-02-27 06:00","pubTimestamp":1772143256,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Inc reports results for the quarter ended September 30 - Earnings SummaryDefinium Therapeutics Inc DFTX.OQ reported a quarterly adjusted loss of 50 cents per share for the quarte","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL8N3ZM3FH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2614079000","title":"Definium Therapeutics Inc. Publishes Corporate Presentation on DT120 ODT Phase 3 Programs for GAD and MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2614079000","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614079000?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:36","pubTimestamp":1772141769,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Inc. released a corporate presentation outlining its strategic focus on generalized anxiety disorder and major depressive disorder and highlighting its late-stage pipeline led by DT120 ODT, an orally disintegrating tablet formulation of lysergide tartrate. The company said DT120 ODT is being evaluated in four Phase 3 studies, with three Phase 3 topline readouts anticipated in 2026, including two pivotal generalized anxiety disorder trials with a primary endpoint of HAM-A at Week 12 and a pivotal major depressive disorder trial with a primary endpoint of MADRS at Week 6. Definium also reported cash, cash equivalents and investments of $411.6 million as of Dec. 31, 2025, with expected runway into 2028. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inform","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL4Bs3Mh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"gpt_icon":0},{"id":"2614759880","title":"Definium Therapeutics Q4 EPS $(0.50) Misses $(0.46) Estimate.","url":"https://stock-news.laohu8.com/highlight/detail?id=2614759880","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614759880?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:03","pubTimestamp":1772139813,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (NASDAQ:DFTX) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.46) by 7.76 percent. This is a 21.95 percent decrease over losses of $(0.41) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50908815/definium-therapeutics-q4-eps-0-50-misses-0-46-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Definium Therapeutics Q4 EPS $(0.50) Misses $(0.46) Estimate.","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"gpt_icon":0},{"id":"2614075616","title":"Definium Therapeutics FY 2025 R&D expenses rise 80.2% to USD 117.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614075616","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614075616?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:02","pubTimestamp":1772139758,"startTime":"0","endTime":"0","summary":"Definium Therapeutics  reported a FY 2025 net loss of USD 183.8 million and a loss from operations of USD 166.3 million, as R&D expenses rose to USD 117.7 million  and G&A expenses increased to USD 48.6 million . Interest income was USD 11.0 million in FY 2025, while interest expense was USD 5.5 million. Cash, cash equivalents and investments totaled USD 411.6 million as of Dec. 31, 2025, and total assets were USD 440.1 million. On the business side, Definium Therapeutics said its Phase 3 MDD trial Emerge is fully enrolled  with topline data anticipated in late Q2 2026, while Phase 3 GAD trial Voyage was about 80% enrolled with topline data expected in early Q3 2026 and no enrollment increase required after a blinded sample size re-estimation. The company also said it initiated a Phase 2a open-label study of DT402  in adults with autism spectrum disorder in Q4 2025, with initial data anticipated in 2026. Definium Therapeutics completed an equity financing in Q4 2025 raising about USD 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDLbjvNdD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2614753040","title":"Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2614753040","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614753040?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:01","pubTimestamp":1772139661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA1G6HGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DFTX"],"gpt_icon":0},{"id":"2614071678","title":"Definium Therapeutics - $411.6 Million in Cash, Cash Equivalents and Investments as of December 31, 2025 Expected to Fund Operations Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2614071678","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614071678?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:01","pubTimestamp":1772139661,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA1G6HGB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2614046087","title":"JonesTrading Remains a Buy on Definium Therapeutics (DFTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614046087","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614046087?lang=en_us&edition=fundamental","pubTime":"2026-02-25 16:45","pubTimestamp":1772009132,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Justin Walsh maintained a Buy rating on Definium Therapeutics yesterday and set a price target of $61.00. The company’s shares...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-remains-a-buy-on-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-remains-a-buy-on-definium-therapeutics-dftx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2613671642","title":"Definium Therapeutics Initiated at Outperform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2613671642","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613671642?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:22","pubTimestamp":1771935720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DFTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2026 07:22 ET (12:22 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"gpt_icon":0},{"id":"2612397352","title":"Press Release: Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612397352","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612397352?lang=en_us&edition=fundamental","pubTime":"2026-02-20 06:42","pubTimestamp":1771540920,"startTime":"0","endTime":"0","summary":"Definium Therapeutics, Inc. , , a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, February 26, 2026 to report financial results for the full year ended December 31, 2025, and discuss recent business updates.The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today's mental health care crisis and enable a healthier future. Headquartered in New York, Definium The","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"gpt_icon":0},{"id":"2612123882","title":"Definium Therapeutics Inc. to Report Full-Year Financial Results via Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2612123882","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612123882?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:01","pubTimestamp":1771534887,"startTime":"0","endTime":"0","summary":"Definium Therapeutics, Inc. will report full-year 2025 financial results on **Thursday, February 26, 2026**, and will host a live webcast at **4:30 p.m. EST** the same day to discuss the results and provide business updates. The webcast can be accessed via link, and a replay will be available on the company’s Investor Relations site at ir.definiumtx.com. Analysts who want to join the Q&A can register via link.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL2bF6y3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2608281396","title":"LSD therapy biotech Definium sued for alleged trade secret theft","url":"https://stock-news.laohu8.com/highlight/detail?id=2608281396","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608281396?lang=en_us&edition=fundamental","pubTime":"2026-02-03 06:05","pubTimestamp":1770069917,"startTime":"0","endTime":"0","summary":"LSD therapy biotechDefinium sued for alleged trade secret theftBy Blake BrittainFeb 2 (Reuters) - A clinical-trial provider sued psychedelic therapy developer Definium Therapeutics DFTX.O on Monday in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nL6N3YY14X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"gpt_icon":0},{"id":"2608970328","title":"Definium Therapeutics Grants Stock Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2608970328","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608970328?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:00","pubTimestamp":1770066025,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Inc. has announced the issuance of inducement grants to two newly hired non-executive employees. The grants consist of options to purchase a total of 28,640 common shares, with an effective grant date of February 2, 2026. The options will vest over four years: 25% will vest on the first anniversary of the grant date, and the remaining 75% will vest in equal monthly increments over the subsequent three years. The exercise price for the options is set at the closing price of Definium’s common shares on the grant date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on February 02, 2026, and is solely responsi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL1lPJh8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"gpt_icon":0},{"id":"2607702998","title":"Definium Therapeutics Initiated at Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2607702998","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607702998?lang=en_us&edition=fundamental","pubTime":"2026-01-31 04:34","pubTimestamp":1769805240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DFTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 30, 2026 15:34 ET (20:34 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.definiumtx.com;ir.definiumtx.com","stockEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.037},{"period":"3month","weight":0.43},{"period":"6month","weight":0.9154},{"period":"1year","weight":1.6717},{"period":"ytd","weight":0.3189}],"compareEarnings":[{"period":"1week","weight":-0.0198},{"period":"1month","weight":-0.0201},{"period":"3month","weight":-0.0194},{"period":"6month","weight":0.0388},{"period":"1year","weight":0.174},{"period":"ytd","weight":-0.014}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.130491},{"month":2,"riseRate":0.8,"avgChangeRate":0.136845},{"month":3,"riseRate":0.4,"avgChangeRate":0.05787},{"month":4,"riseRate":0.75,"avgChangeRate":0.007711},{"month":5,"riseRate":0.4,"avgChangeRate":-0.002468},{"month":6,"riseRate":0.4,"avgChangeRate":-0.111207},{"month":7,"riseRate":0.8,"avgChangeRate":0.20763},{"month":8,"riseRate":0.2,"avgChangeRate":-0.091548},{"month":9,"riseRate":0.2,"avgChangeRate":-0.174855},{"month":10,"riseRate":0.6,"avgChangeRate":0.009639},{"month":11,"riseRate":0.4,"avgChangeRate":0.026551},{"month":12,"riseRate":0.4,"avgChangeRate":-0.08416}],"exchange":"NASDAQ","name":"Definium Therapeutics","nameEN":"Definium Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Definium Therapeutics(DFTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Definium Therapeutics(DFTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Definium Therapeutics,DFTX,Definium Therapeutics股票,Definium Therapeutics股票老虎,Definium Therapeutics股票老虎国际,Definium Therapeutics行情,Definium Therapeutics股票行情,Definium Therapeutics股价,Definium Therapeutics股市,Definium Therapeutics股票价格,Definium Therapeutics股票交易,Definium Therapeutics股票购买,Definium Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Definium Therapeutics(DFTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Definium Therapeutics(DFTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}